Figure 2.

cRabMab1-hIgG1 suppresses tumor growth and has favorable pharmacokinetics. cRabMab1-hIgG1 was assessed for asTF binding in vitro, effects on tumor growth, and pharmacokinetics. (A) Western blot of Pt45.P1, PaCa44, AsPC1 and MIA-PaCa2 lysates (30 ug each). Each blot was probed with the indicated antibody at 1 µg/mL (B) qPCR for total TF transcripts showing relative expression levels. (C) qPCR for flTF transcripts showing relative expression levels. (D) qPCR for asTF transcripts showing relative expression levels. (E) Migration assay with Pt45.P1 cells treated as indicated. (F) Tumor weights - 1x10⁶ Pt45.P1 cells were incubated with either 100 µg of rIgG, 100 µg cRabMab1-hIgG1, or an equal volume of vehicle and implanted into the pancreata of athymic nude mice (n = 7/group); tumors grew for 45 days before sacrifice. (G) Plasma levels of cRabMab1-hIgG1 resulting from a single injection of 18 mg/kg of the antibody in C57Bl/6 mice. (H) PK analysis of cRabMab1-hIgG1. *p ≤ 0.05; **p ≤ 0.01; ns, not significant.